Recombinant Human TNFRSF13B/CD267 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human TNFRSF13B/CD267 protein (rFc Tag) (Eg1638)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1638

---

Validation Data Gallery

• 

  Purity of Recombinant Human TNFRSF13B was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human TNFRSF13B protein Ser2-Thr166 (Accession# O14836-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 23495
• Accession: O14836-1
• PredictedSize: 44.8 kDa
• SDS-PAGE: 32-38 kDa and 44-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

TNFRSF13B encodes the transmembrane activator and CAML interactor (TACI) receptor, which drives plasma cell differentiation.TACI is the receptor for the B cell–activating factor (BAFF) and a proliferation-induced ligand (APRIL). TNFRSF13B is expressed as long (L) or short (S) isoforms generated by alternative splicing of exon 2, typically after B cell activation. TNFRSF13B-S lacks the cysteine rich domain 1 needed for binding ligands but retains ability to for receptor trimers and to signal. Indeed, TNFRSF13B complexes containing both -S and -L isoforms may exhibit greater sensitivity to agonists than complexes consisting of only L isoform.

References:

1. Cascalho, Marilia, et al. (2023) Hum Immunol.84(1):27-33. 
2. Platt, Jeffrey L et al. (2021) JCI Insight.6(14):e148208.
3. de Mattos Barbosa, Mayara Garcia et al. (2021) JCI Insight.6(17):e150483.